Loading...
Loading...
CAPR| Name | Value |
|---|---|
| Revenues | 11.1M |
| Cost of Revenue | 0.4M |
| Gross Profit | 10.8M |
| Operating Expense | 18.5M |
| Operating I/L | -7.7M |
| Other Income/Expense | 0.6M |
| Interest Income | 0.7M |
| Pretax | -7.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -7.1M |
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company specializing in cell and exosome-based therapeutics for various diseases. Its lead candidate, CAP-1002, is a cardiac-derived cell therapy undergoing phase III clinical trials for Duchenne muscular dystrophy and phase II trials for cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 for trauma-related injuries and conditions, along with vaccine candidates for potential COVID-19 prevention. Capricor collaborates with Lonza Houston, Inc. for clinical manufacturing. The company generates revenue through the development and commercialization of its therapeutic candidates and potential vaccines.
